Guangdong Zhongsheng Pharma Initiates Phase IIb Study for ZSP1601 in NASH
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the first subject enrollment in...
Clinical trial approval / initiation
Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G
Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical...
Jiangsu Hengrui Medicine’s SHR-1905 and SHR7280 Receive NMPA Clinical Trial Approvals
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals from...
Brii Biosciences Initiates Phase I Study for BRII-297 in Australia
China’s Brii Biosciences (HKG: 2137) has announced the first patient dosing in a Phase I...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-2106 and HRS-1893 Clinical Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has separately announced receiving clinical trial approvals...
Hisun Pharmaceutical’s SHP2 Inhibitor HS336 Gets NMPA Clinical Trial Approval
Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it...
Accropeutics Receives HREC Approval for AC-201 Phase I Trial
Suzhou-based Accro Bioscience (Suzhou) Limited (Accropeutics) has announced that it has received approval from the...
Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation...
Mabwell Bioscience’s 9MW3811 Receives NMPA Approval for Clinical Trials in Oncology and Fibrosis
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...
Hanx Biopharmaceuticals’ HX009 Receives US IND Approval for Lymphoma Treatment
Wuhan-based firm Hanx Biopharmaceuticals Inc. has announced the receipt of an Investigational New Drug (IND)...
Minghui Pharmaceutical Initiates First-in-Human Trial for IGF-1R Antibody Fusion Protein MHB018A
China-based Minghui Pharmaceutical Inc. has announced the commencement of a first-in-human Phase Ia trial for...
3SBio Inc. Initiates Phase III Clinical Study for Thrombopoietin in Chronic Liver Disease Patients
China-based 3SBio Inc. (HKG: 1530) has announced the enrollment of the first patient in a...
Zhejiang Conba Pharmaceutical’s Inhalable Pirfenidone for IPF Clears for Chinese Clinical Trials
Zhejiang Conba Pharmaceutical Co., Ltd (SHA: 600572) has announced that its modified version of US...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Two Autoimmune Disease Drug Candidates
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has separately announced clinical trial approvals from the National...
Sino-US Laekna Receives FDA Clearance for LAE102 Clinical Trial in NSCLC
Sino-US Laekna has announced that it has received clinical trial clearance from the US Food...
Cabaletta Bio’s CABA-201 Clears FDA for Phase I/II Study in Idiopathic Inflammatory Myopathy
US-based Cabaletta Bio, Inc. (NASDAQ: CABA) has announced that the US Food and Drug Administration...
Betta Pharmaceuticals Initiates Phase I/II Study for First-In-Class BsAb BPB-101
China’s Betta Pharmaceuticals (SHE: 300558) has announced the enrollment of the first patient in a...
Antengene’s First-in-Class CD24 mAb ATG-031 Gets US FDA Approval for Phase I Study
Antengene Corp., Ltd (HKG: 6996) has announced that it has received approval from the US...
WestVac Biopharma Receives FDA Approval for COVID-19 Protein Vaccines Targeting XBB Variants
Chengdu-based WestVac Biopharma Co., Ltd has announced receiving clinical trial approval from the National Medical...
CARSgen Therapeutics Initiates Phase II Study for CT041 in Advanced Gastric Cancer
China-based chimeric antigen receptor (CAR)-T cell specialist CARSgen Therapeutics Holdings Ltd (HKG: 2171) has announced...